Piper Jaffray Companies set a $20.00 price objective on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in a research report sent to investors on Saturday. The brokerage currently has a buy rating on the stock.

A number of other analysts also recently weighed in on AMPH. Jefferies Group LLC set a $21.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a buy rating in a report on Thursday, April 20th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, May 16th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a c rating to a b- rating in a report on Monday, June 26th. Wells Fargo & Company reiterated a buy rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. Finally, BidaskClub downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Amphastar Pharmaceuticals presently has a consensus rating of Buy and an average price target of $20.14.

Amphastar Pharmaceuticals (AMPH) opened at 16.67 on Friday. The company has a 50-day moving average price of $17.52 and a 200-day moving average price of $15.94. The company has a market cap of $762.45 million, a PE ratio of 79.38 and a beta of 1.68. Amphastar Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Monday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by $0.03. The company had revenue of $56.67 million during the quarter, compared to analysts’ expectations of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.12 EPS. On average, analysts expect that Amphastar Pharmaceuticals will post $0.40 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Amphastar Pharmaceuticals, Inc. (AMPH) PT Set at $20.00 by Piper Jaffray Companies” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/amphastar-pharmaceuticals-inc-amph-pt-set-at-20-00-by-piper-jaffray-companies/1465950.html.

In other Amphastar Pharmaceuticals news, Director Jason B. Shandell sold 11,482 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $16.92, for a total transaction of $194,275.44. Following the transaction, the director now owns 241,342 shares in the company, valued at approximately $4,083,506.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard K. Prins sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $15.43, for a total transaction of $115,725.00. Following the transaction, the director now owns 30,500 shares in the company, valued at approximately $470,615. The disclosure for this sale can be found here. Insiders sold a total of 43,982 shares of company stock valued at $735,850 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its stake in Amphastar Pharmaceuticals by 6.2% in the fourth quarter. State Street Corp now owns 955,991 shares of the company’s stock worth $17,610,000 after buying an additional 55,688 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock worth $14,753,000 after buying an additional 324,043 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Amphastar Pharmaceuticals by 2.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 19,440 shares of the company’s stock worth $358,000 after buying an additional 400 shares during the last quarter. Teachers Advisors LLC raised its stake in Amphastar Pharmaceuticals by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 542,953 shares of the company’s stock worth $10,001,000 after buying an additional 1,693 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock worth $212,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 44.72% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.